Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solutions × Dermatologic × Clear all
NCT03322293 2022-03-09

Daylight Photodynamic Therapy for Actinic Keratosis

University of California, San Francisco

Phase 1 Completed
24 enrolled 15 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡